Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
48 hedge funds and large institutions have $70M invested in Mersana Therapeutics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
4% more funds holding
Funds holding: 46 → 48 (+2)
0.46% less ownership
Funds ownership: 3.42% → 2.96% (-0.46%)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
65% less capital invested
Capital invested by funds: $198M → $70M (-$128M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.48M |
| 2 |
JG
Jefferies Group
New York
|
+$2.13M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.18M |
| 4 |
JP Morgan Chase
New York
|
+$674K |
| 5 |
HP
Hikari Power
Tokyo,
Japan
|
+$540K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.96M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.12M |
| 4 |
Millennium Management
New York
|
-$2.06M |
| 5 |
BlackRock
New York
|
-$1.54M |
MRSN Hedge Fund Activity: Q4 2018 in Review
48 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q4 2018, worth a combined $70M — down 65% from $198M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MRSN positions and 6 closed out — a net gain of 3 holders — while 12 added to existing stakes and 15 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.48M. The largest seller was Wellington Management Group, cutting an estimated $11.2M.
- 48 institutional investors held Mersana Therapeutics (MRSN) as of Q4 2018, up from 46 in Q3 2018.
- Funds reported $70M of Mersana Therapeutics stock for Q4 2018, down 65% quarter-over-quarter.
- 9 funds opened new Mersana Therapeutics positions in Q4 2018 and 6 closed out, a net change of +3 holders.
- The largest Mersana Therapeutics buyer in Q4 2018 was Point72 Asset Management, an estimated $3.48M added.
- The largest Mersana Therapeutics seller in Q4 2018 was Wellington Management Group, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2018.